Trial Profile
Double Blind, Randomized Study Assessing the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses or Multiple Ascending Doses of APX-115 in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Mar 2019
Price :
$35
*
At a glance
- Drugs Isuzinaxib (Primary)
- Indications Diabetic neuropathies
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AptaBio Therapeutics
- 07 Mar 2019 Status changed from recruiting to completed.
- 22 Mar 2018 New trial record